The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Influence of mild and moderate hepatic impairment on the pharmacokinetics (PK) of the pan-HER inhibitor dacomitinib.
Nagdeep Giri
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Research Funding - Pfizer
Anna Plotka
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Yali Liang
Employment or Leadership Position - Pfizer
Tanya Boutros
Employment or Leadership Position - Pfizer
Grace Ni
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer (I); Pfizer
Joanna Masters
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Michael DeMicco
No relevant relationships to disclose
Patricia Pardo
No relevant relationships to disclose
Carlo Bello
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Joseph O'Connell
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer